Improving tumor response to radiotherapy by targeting angiogenesis signaling pathways

Phyllis Wachsberger; Randy Burd; Adam P. Dicker

doi:10.1016/j.hoc.2004.06.007

Improving tumor response to radiotherapy by targeting angiogenesis signaling pathways

Phyllis Wachsberger
, Randy Burd
, Adam P. Dicker

Research output: Contribution to journal › Review article › peer-review

34 Scopus citations

Abstract

Radiotherapy is one of the most widely used treatments for cancer; however, the development of tumor radioresistance is an ongoing problem. Agents that target tumor angiogenesis are being used in combination with radiotherapy to improve the therapeutic index without a clear understanding of how these agents may affect radiosensitization. This article discusses recently published studies that may shed some light on the underlying signaling mechanisms that are involved in the interactions of antiangiogenic agents with ionizing radiation.

Original language	English (US)
Pages (from-to)	1039-1057
Number of pages	19
Journal	Hematology/Oncology Clinics of North America
Volume	18
Issue number	5
DOIs	https://doi.org/10.1016/j.hoc.2004.06.007
State	Published - Oct 2004
Externally published	Yes

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1016/j.hoc.2004.06.007

Cite this

@article{b96b7e4751d54c56ba3a5e7997a6f004,

title = "Improving tumor response to radiotherapy by targeting angiogenesis signaling pathways",

abstract = "Radiotherapy is one of the most widely used treatments for cancer; however, the development of tumor radioresistance is an ongoing problem. Agents that target tumor angiogenesis are being used in combination with radiotherapy to improve the therapeutic index without a clear understanding of how these agents may affect radiosensitization. This article discusses recently published studies that may shed some light on the underlying signaling mechanisms that are involved in the interactions of antiangiogenic agents with ionizing radiation.",

author = "Phyllis Wachsberger and Randy Burd and Dicker, \{Adam P.\}",

note = "Funding Information: This work was supported in part by P30CA56036-03 (NCI), a Bridge Grant to Dr. Dicker from the Office of the Dean, Thomas Jefferson University, and seed grants from the Radiation Therapy Oncology Group (RTOG) to Drs. Wachsberger and Dicker as well as a grant to the Radiation Therapy Oncology Group (Commonwealth of Pennsylvania, Tobacco Settlement Act) to Drs. Burd and Dicker. Dr. Wachsberger has unrestricted grants from AstraZeneca, Regeneron, and Abbot pharmaceuticals. Dr. Dicker has unrestricted grants from Pharmacia, Regeneron, and AstraZeneca. Dr. Burd has unrestricted grants from Aventis, Regeneron, and AstraZeneca. ",

year = "2004",

month = oct,

doi = "10.1016/j.hoc.2004.06.007",

language = "English (US)",

volume = "18",

pages = "1039--1057",

journal = "Hematology/Oncology Clinics of North America",

issn = "0889-8588",

publisher = "W.B. Saunders",

number = "5",

}

TY - JOUR

T1 - Improving tumor response to radiotherapy by targeting angiogenesis signaling pathways

AU - Wachsberger, Phyllis

AU - Burd, Randy

AU - Dicker, Adam P.

N1 - Funding Information: This work was supported in part by P30CA56036-03 (NCI), a Bridge Grant to Dr. Dicker from the Office of the Dean, Thomas Jefferson University, and seed grants from the Radiation Therapy Oncology Group (RTOG) to Drs. Wachsberger and Dicker as well as a grant to the Radiation Therapy Oncology Group (Commonwealth of Pennsylvania, Tobacco Settlement Act) to Drs. Burd and Dicker. Dr. Wachsberger has unrestricted grants from AstraZeneca, Regeneron, and Abbot pharmaceuticals. Dr. Dicker has unrestricted grants from Pharmacia, Regeneron, and AstraZeneca. Dr. Burd has unrestricted grants from Aventis, Regeneron, and AstraZeneca.

PY - 2004/10

Y1 - 2004/10

N2 - Radiotherapy is one of the most widely used treatments for cancer; however, the development of tumor radioresistance is an ongoing problem. Agents that target tumor angiogenesis are being used in combination with radiotherapy to improve the therapeutic index without a clear understanding of how these agents may affect radiosensitization. This article discusses recently published studies that may shed some light on the underlying signaling mechanisms that are involved in the interactions of antiangiogenic agents with ionizing radiation.

AB - Radiotherapy is one of the most widely used treatments for cancer; however, the development of tumor radioresistance is an ongoing problem. Agents that target tumor angiogenesis are being used in combination with radiotherapy to improve the therapeutic index without a clear understanding of how these agents may affect radiosensitization. This article discusses recently published studies that may shed some light on the underlying signaling mechanisms that are involved in the interactions of antiangiogenic agents with ionizing radiation.

UR - https://www.scopus.com/pages/publications/5044223266

UR - https://www.scopus.com/pages/publications/5044223266#tab=citedBy

U2 - 10.1016/j.hoc.2004.06.007

DO - 10.1016/j.hoc.2004.06.007

M3 - Review article

C2 - 15474334

AN - SCOPUS:5044223266

SN - 0889-8588

VL - 18

SP - 1039

EP - 1057

JO - Hematology/Oncology Clinics of North America

JF - Hematology/Oncology Clinics of North America

IS - 5

ER -

Improving tumor response to radiotherapy by targeting angiogenesis signaling pathways

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this